xemilofiban has been researched along with aspirin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuchi, S; Kondo, K; Nakashima, M; Nishiyama, H; Umemura, K | 1 |
| Anders, RJ; Burns, DM; Cove, CS; DeFranco, AC; Ellis, SG; Kottke-Marchant, K; Lowrie, M; Miller, DP; Moliterno, DJ; Raymond, RE; Simpfendorfer, C; Sutton, JM; Topol, EJ | 1 |
| Anders, RJ; Broderick, TM; Ferguson, JJ; Hantsbarger, G; Higby, NA; Kereiakes, DJ; Kleiman, N; Martin, LH; McDonald, S; Runyon, JP | 1 |
| Feigen, LP; Frederick, LG; King, LW; Nicholson, NS; Salyers, AK; Suleymanov, OD; Szalony, JA; Taite, BB | 1 |
| Kereiakes, DJ | 1 |
| Ferguson, JJ | 1 |
| McGuire, DK; Newby, LK | 1 |
| Bhatt, DL; Chew, DP; Sapp, S; Topol, EJ | 1 |
| Davis, CJ; Lowry, DR; McKenzie, ME; Nair, GV; Serebruany, VL | 1 |
| Tendera, M; Wojakowski, W | 1 |
5 review(s) available for xemilofiban and aspirin
| Article | Year |
|---|---|
Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy?
Topics: Abciximab; Administration, Oral; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Benzamidines; Clinical Trials as Topic; Drug Synergism; Epistaxis; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex | 1999 |
Oral platelet glycoprotein IIb/IIIa inhibition.
Topics: Alanine; Angina, Unstable; Aspirin; Benzamidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Myocardial Infarction; Oximes; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Syndrome; Treatment Outcome | 2000 |
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Topics: Administration, Oral; Alanine; Aspirin; Benzamidines; Clinical Trials, Phase III as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Oximes; Piperidines; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |
Aspirin in patients with coronary artery disease: is it simply irresistible?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Benzamidines; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Diabetes Complications; Dipyridamole; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelium, Vascular; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Oximes; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Randomized Controlled Trials as Topic; Stroke; Thrombosis; Thromboxane-A Synthase; Ticlopidine; Vasodilator Agents | 2001 |
Role of antiplatelet drugs in the prevention of cardiovascular events.
Topics: Aspirin; Benzamidines; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Oximes; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Stroke; Ticlopidine; Treatment Outcome | 2003 |
2 trial(s) available for xemilofiban and aspirin
| Article | Year |
|---|---|
First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions.
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Benzamidines; Coronary Artery Bypass; Diabetes Mellitus, Type 1; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex | 1997 |
Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
Topics: Abciximab; Administration, Oral; Aged; Antibodies, Monoclonal; Aspirin; Benzamidines; Coronary Disease; Dose-Response Relationship, Drug; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Single-Blind Method; Stents; Thrombosis; Ticlopidine | 1997 |
3 other study(ies) available for xemilofiban and aspirin
| Article | Year |
|---|---|
Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Benzamidines; Cell Movement; Cells, Cultured; Coronary Disease; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelium, Vascular; Femoral Artery; Guinea Pigs; Male; Microscopy, Electron, Scanning; Muscle, Smooth, Vascular; Photochemistry; Plasminogen Activators; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Reactive Oxygen Species; Recombinant Proteins; Recurrence; Rose Bengal | 1996 |
Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirin.
Topics: Administration, Oral; Animals; Arterial Occlusive Diseases; Aspirin; Benzamidines; Binding Sites; Dogs; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Electric Stimulation; Female; Male; Platelet Aggregation Inhibitors; Templates, Genetic; Thrombosis | 1998 |
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal; Aspirin; Benzamidines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Disease; Dalteparin; Defibrillators, Implantable; Double-Blind Method; Enalapril; Endothelial Growth Factors; Fatty Acids, Omega-3; Guanidines; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Laser Therapy; Lymphokines; Metoprolol; Multicenter Studies as Topic; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pyrrolidines; Randomized Controlled Trials as Topic; Simvastatin; Sodium-Hydrogen Exchangers; Stents; Sulfones; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vitamin E | 1999 |